Ex­elix­is pulls a sur­prise win in thy­roid can­cer just days ahead of fi­nal Cabome­tyx read­out

Ex­elix­is added a thy­roid can­cer in­di­ca­tion to its su­per-sell­er Cabome­tyx’s la­bel on Fri­day — months be­fore the FDA was ex­pect­ed to make a de­ci­sion, and days be­fore the com­pa­ny was set to un­veil the fi­nal da­ta at #ES­MO21.

At a me­di­an fol­low-up of 10.1 months, dif­fer­en­ti­at­ed thy­roid can­cer pa­tients treat­ed with Cabome­tyx (cabozan­ti­nib) lived a me­di­an of 11 months with­out their dis­ease wors­en­ing, com­pared to just 1.9 months for pa­tients giv­en a place­bo, Ex­elix­is said on Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER